Use of GnRH agonists to support the luteal phase during infertility treatment
First Claim
1. A method of treating infertility in a female mammal comprising administering a pharmaceutical agent comprising a gonadotrophin releasing hormone (GnRH) agonist in an amount and for a time sufficient to support the luteal phase, wherein the GnRH agonist is administered to the female mammal beginning within the first three days after ovulation in the female mammal and for at least 7 days thereafter eitheri) after spontaneous ovulation in the female mammal, orii) after stimulation of follicular growth and triggering of final follicular maturation followed by an ovulation in the female mammal by administration of at least one additional agent,such that infertility is treated in the female mammal.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of woman. According to this invention, the pharmaceutical agent is suitable to be used for supporting the luteal phase after a spontaneous ovulation or after stimulation of follicular growth, trigger of final follicular maturation and ovulation with one or several additional agents.
-
Citations
30 Claims
-
1. A method of treating infertility in a female mammal comprising administering a pharmaceutical agent comprising a gonadotrophin releasing hormone (GnRH) agonist in an amount and for a time sufficient to support the luteal phase, wherein the GnRH agonist is administered to the female mammal beginning within the first three days after ovulation in the female mammal and for at least 7 days thereafter either
i) after spontaneous ovulation in the female mammal, or ii) after stimulation of follicular growth and triggering of final follicular maturation followed by an ovulation in the female mammal by administration of at least one additional agent, such that infertility is treated in the female mammal.
-
26. A method of treating infertility in a female mammal comprising administering a pharmaceutical agent which comprises a GnRH agonist comprising buserelin, which supports luteal phase after stimulation of follicular growth and induction of final follicular maturation and ovulation with one or more additional agents, wherein said buserelin is administered intra-nasally within the first three days following ovulation trigger at a dose of between 50 and 400 μ
- g and at a frequency between three times a day and once every three days for a duration of 7 to 14 days, such that infertility in the female mammal is treated.
- View Dependent Claims (27, 28, 29)
-
30. A method of treating infertility in a female mammal comprising administering a pharmaceutical agent which comprises a GnRH agonist comprising buserelin, which supports luteal phase after stimulation of follicular growth and induction of final follicular maturation and ovulation with one or more additional agents, wherein said buserelin is administered intra-nasally within the first three days following ovulation trigger at a dose of between 50 and 400 μ
- g and at a frequency between three times a day and once every three days for a duration of up to 28 days in a female mammal that has conceived, such that infertility in the female mammal is treated.
Specification